Скачать с ютуб Research and Treatment Development for SCA5 в хорошем качестве

Research and Treatment Development for SCA5

SCA5 is a rare neuromuscular disease. The National Ataxia Foundation is proud to host this webinar presented by Dr. Adam Avery on March 19th, 2024. In "Research and Treatment for SCA5", he gave an overview of how it is studied and gave an overview of the current state of research and drug development for the disease. For more information on Ataxia, please visit our website: https://www.ataxia.org Become a Free NAF member! https://bit.ly/JoinNAF Follow us on Social Media! NAF Facebook:   / ataxiafounda.  . NAF Twitter:   / naf_ataxia   NAF Instagram:   / ataxiafound.  . Ataxia Subreddit:   / ataxia   About the Speaker- Speaker: Adam Avery, PhD Title: Assistant Professor of Biochemistry Institution: Oakland University Bio: Adam Avery, PhD has an undergraduate degree in biochemistry from Oakland University. He earned his PhD in biological chemistry at the University of Michigan. As a graduate student in Anne Vojtek’s lab, Adam gained expertise in protein-protein interaction experimental approaches, including the yeast-two hybrid. As graduate student, Adam was a fellow on an NIH Cellular Biotechnology Training Program. Following completion of his PhD, Adam worked in the biotech industry, where he developed cell-based assays for primary and secondary drug screening. Subsequently, he performed post-doctoral studies in Thomas Hays’ lab at the University of Minnesota. As a post-doc, Adam commenced his studies of the molecular and cellular mechanisms underlying SCA5. This work combined protein biochemistry and genetic and cell biological approaches in the model organism, Drosophila. Adam also developed a patented cell-based assay to identify small molecule modulators of beta-III-spectrin, the SCA5 disease protein. Adam is currently an Assistant Professor of Biochemistry at Oakland University. His research program reflects his broad training in biochemistry, genetics and drug screening. Adam’s lab has continued to make important contributions to our understanding SCA5 disease mechanisms. Further, his research lab has contributed to a collaborative SCA5 drug discovery project.